Skip to main content

Dr. Chethan Ramamurthy, MD

Medical Oncology (Medical Oncology Physician)

  • Medicare participating

At a glance

Medical school
Baylor College of Medicine (2012)
Years since graduation
14
In the NPI registry since
2012
Medicare patients seen, 2024
12

Licensed in Texas since 2018, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2012Medical school: Baylor College of Medicine
  • 2012Registered with an NPI (national billing number; not a license date)

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Medical Oncology Physician primary
    TX license R8082 (first issued 2018; active)
  • Internal Medicine Physician
    TX license R8082 (first issued 2018; active)

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Medical Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
12
Services billed
56
Patients’ average age
74
Most frequent Medicare services, 2023
ServiceTimesPatients
Injection, ondansetron hydrochloride, per 1 mg47625
Injection, dexamethasone sodium phosphate, 1 mg39625
Established patient office or other outpatient visit, 30-39 minutes11174
Injection of additional new drug or substance into vein8134
Administration of chemotherapy into vein, 1 hour or less6148
Established patient office or other outpatient visit, 40-54 minutes5646
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less4528
Administration of chemotherapy into vein, each additional hour2113
Injection of drug or substance under skin or into muscle1915
Injection, diphenhydramine hcl, up to 50 mg1715

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Industry-funded research

Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $338 in research payments for these studies, mostly to the institutions running them.

  • A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus Bempegaldesleukin (NKTR214), Versus Nivolumab Alone Versus Standard of Care in Participants With MuscleInvasive Bladder Cancer (MIBC) Who Are Cis…
    E.r. Squibb & Sons, L.l.c.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in San Antonio

Sources

NPI registry (CMS NPPES, November 2026; record last updated October 17, 2018), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1376805457. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.